Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 15 November 2024, including: muscling into the obesity market; AbbVie’s schizophrenia failure; Bayer will not take risky bets; generally strong Q2 for Japanese majors; and AstraZeneca juggles China and growth questions.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
Muscling Into The Obesity Market
Value Of AbbVie’s Cerevel Buy Uncertain After Schizophrenia Failure
Bayer Will Not Take Risky Bets To Close Xarelto Revenue Gap
Japan H1 Roundup: Forex Impact, Strong Global Mainstays Positive Factors
AstraZeneca Juggles Questions About China Scrutiny And US Growth Strategy